Listed

Protalix BioTherapeutics, Inc.

PLXNYSECIK 1006281HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$19.9m, Q2 FY2026
Operating income$4.7m, Q2 FY2026
Net income$3.8m, Q2 FY2026
Protalix BioTherapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m10.3Revenue, Q3 FY2023, three months to 2023-09-30$10.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure10.5Revenue, Q4 FY2023, three months to 2023-12-31$10.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure3.7Revenue, Q1 FY2024, three months to 2024-03-31$3.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure13.5Revenue, Q2 FY2024, three months to 2024-06-30$13.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure18.0Revenue, Q3 FY2024, three months to 2024-09-30$18.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure18.2Revenue, Q4 FY2024, three months to 2024-12-31$18.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure10.1Revenue, Q1 FY2025, three months to 2025-03-31$10.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure15.7Revenue, Q2 FY2025, three months to 2025-06-30$15.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure17.9Revenue, Q3 FY2025, three months to 2025-09-30$17.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure9.1Revenue, Q4 FY2025, three months to 2025-12-31$9.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure33.8Revenue, Q1 FY2026, three months to 2026-03-31$33.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure19.9Revenue, Q2 FY2026, three months to 2026-06-30$19.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Cost of revenue$m4.9Cost of revenue, Q3 FY2023, three months to 2023-09-30$4.9m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure8.9Cost of revenue, Q4 FY2023, three months to 2023-12-31$8.9m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure2.6Cost of revenue, Q1 FY2024, three months to 2024-03-31$2.6m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure9.5Cost of revenue, Q2 FY2024, three months to 2024-06-30$9.5m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure8.4Cost of revenue, Q3 FY2024, three months to 2024-09-30$8.4m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure3.9Cost of revenue, Q4 FY2024, three months to 2024-12-31$3.9m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure8.2Cost of revenue, Q1 FY2025, three months to 2025-03-31$8.2m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure5.9Cost of revenue, Q2 FY2025, three months to 2025-06-30$5.9m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure8.3Cost of revenue, Q3 FY2025, three months to 2025-09-30$8.3m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure4.6Cost of revenue, Q4 FY2025, three months to 2025-12-31$4.6m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure4.1Cost of revenue, Q1 FY2026, three months to 2026-03-31$4.1m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure7.8Cost of revenue, Q2 FY2026, three months to 2026-06-30$7.8m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Gross profit$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m3.7Research and development, Q3 FY2023, three months to 2023-09-30$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure3.1Research and development, Q4 FY2023, three months to 2023-12-31$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure2.9Research and development, Q1 FY2024, three months to 2024-03-31$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure3.0Research and development, Q2 FY2024, three months to 2024-06-30$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure3.0Research and development, Q3 FY2024, three months to 2024-09-30$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure4.1Research and development, Q4 FY2024, three months to 2024-12-31$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure3.5Research and development, Q1 FY2025, three months to 2025-03-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure6.0Research and development, Q2 FY2025, three months to 2025-06-30$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure4.5Research and development, Q3 FY2025, three months to 2025-09-30$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure5.6Research and development, Q4 FY2025, three months to 2025-12-31$5.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure5.4Research and development, Q1 FY2026, three months to 2026-03-31$5.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure4.4Research and development, Q2 FY2026, three months to 2026-06-30$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Selling, general and administrative$m3.7Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$3.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure4.1Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$4.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure3.1Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$3.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure3.5Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$3.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure2.6Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$2.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure3.0Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$3.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure2.6Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$2.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure2.6Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$2.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure2.9Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$2.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure3.5Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$3.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure3.1Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$3.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure3.1Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$3.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Operating income$m(1.9)Operating income, Q3 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure(5.6)Operating income, Q4 FY2023, three months to 2023-12-31−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(4.9)Operating income, Q1 FY2024, three months to 2024-03-31−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(2.4)Operating income, Q2 FY2024, three months to 2024-06-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure4.0Operating income, Q3 FY2024, three months to 2024-09-30$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure7.2Operating income, Q4 FY2024, three months to 2024-12-31$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(4.1)Operating income, Q1 FY2025, three months to 2025-03-31−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure1.2Operating income, Q2 FY2025, three months to 2025-06-30$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure2.1Operating income, Q3 FY2025, three months to 2025-09-30$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure(4.7)Operating income, Q4 FY2025, three months to 2025-12-31−$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure21.1Operating income, Q1 FY2026, three months to 2026-03-31$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure4.7Operating income, Q2 FY2026, three months to 2026-06-30$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.1Income tax, Q3 FY2023, three months to 2023-09-30$133.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure(0.4)Income tax, Q4 FY2023, three months to 2023-12-31−$382.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(0.1)Income tax, Q1 FY2024, three months to 2024-03-31−$138.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(0.1)Income tax, Q2 FY2024, three months to 2024-06-30−$69.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure0.6Income tax, Q3 FY2024, three months to 2024-09-30$607.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure0.8Income tax, Q4 FY2024, three months to 2024-12-31$822.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(0.1)Income tax, Q1 FY2025, three months to 2025-03-31−$113.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.5Income tax, Q2 FY2025, three months to 2025-06-30$497.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure(0.1)Income tax, Q3 FY2025, three months to 2025-09-30−$116.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure0.7Income tax, Q4 FY2025, three months to 2025-12-31$728.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure2.8Income tax, Q1 FY2026, three months to 2026-03-31$2.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure1.1Income tax, Q2 FY2026, three months to 2026-06-30$1.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Net income$m(1.9)Net income, Q3 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure(6.0)Net income, Q4 FY2023, three months to 2023-12-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Net income, Q1 FY2024, three months to 2024-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(2.2)Net income, Q2 FY2024, three months to 2024-06-30−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure3.2Net income, Q3 FY2024, three months to 2024-09-30$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure6.5Net income, Q4 FY2024, three months to 2024-12-31$6.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(3.6)Net income, Q1 FY2025, three months to 2025-03-31−$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.2Net income, Q2 FY2025, three months to 2025-06-30$164.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure2.4Net income, Q3 FY2025, three months to 2025-09-30$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure(5.5)Net income, Q4 FY2025, three months to 2025-12-31−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure18.3Net income, Q1 FY2026, three months to 2026-03-31$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure3.8Net income, Q2 FY2026, three months to 2026-06-30$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Diluted EPS$ per share(0.04)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figurenot reported(0.06)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(0.03)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure0.03Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figurenot reported(0.05)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.00Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure0.03Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figurenot reported0.22Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.05Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Basic EPS$ per share(0.03)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figurenot reported(0.06)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(0.03)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure0.04Basic EPS, Q3 FY2024, three months to 2024-09-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figurenot reported(0.05)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.00Basic EPS, Q2 FY2025, three months to 2025-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure0.03Basic EPS, Q3 FY2025, three months to 2025-09-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figurenot reported0.23Basic EPS, Q1 FY2026, three months to 2026-03-31$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.05Basic EPS, Q2 FY2026, three months to 2026-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure

Balance sheet

Cash and equivalents$27.4m, Q2 FY2026
Shareholders' equity$71.4m, Q2 FY2026
Protalix BioTherapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m20.4Cash and equivalents, Q3 FY2023, at 2023-09-30$20.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure23.6Cash and equivalents, FY2023, at 2023-12-31$23.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-17, accession 0001558370-25-003039.Report this figure27.2Cash and equivalents, Q1 FY2024, at 2024-03-31$27.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure23.4Cash and equivalents, Q2 FY2024, at 2024-06-30$23.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure27.4Cash and equivalents, Q3 FY2024, at 2024-09-30$27.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure19.8Cash and equivalents, FY2024, at 2024-12-31$19.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure19.5Cash and equivalents, Q1 FY2025, at 2025-03-31$19.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure17.9Cash and equivalents, Q2 FY2025, at 2025-06-30$17.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure13.6Cash and equivalents, Q3 FY2025, at 2025-09-30$13.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure14.7Cash and equivalents, FY2025, at 2025-12-31$14.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure41.0Cash and equivalents, Q1 FY2026, at 2026-03-31$41.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure27.4Cash and equivalents, Q2 FY2026, at 2026-06-30$27.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Current assets$m72.6Current assets, Q3 FY2023, at 2023-09-30$72.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure69.9Current assets, FY2023, at 2023-12-31$69.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-17, accession 0001558370-25-003039.Report this figure75.4Current assets, Q1 FY2024, at 2024-03-31$75.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure77.4Current assets, Q2 FY2024, at 2024-06-30$77.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure47.9Current assets, Q3 FY2024, at 2024-09-30$47.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure60.1Current assets, FY2024, at 2024-12-31$60.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure60.5Current assets, Q1 FY2025, at 2025-03-31$60.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure65.5Current assets, Q2 FY2025, at 2025-06-30$65.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure66.5Current assets, Q3 FY2025, at 2025-09-30$66.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure66.7Current assets, FY2025, at 2025-12-31$66.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure86.4Current assets, Q1 FY2026, at 2026-03-31$86.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure92.2Current assets, Q2 FY2026, at 2026-06-30$92.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Total assets$m87.6Total assets, Q3 FY2023, at 2023-09-30$87.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure84.4Total assets, FY2023, at 2023-12-31$84.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-17, accession 0001558370-25-003039.Report this figure89.8Total assets, Q1 FY2024, at 2024-03-31$89.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure91.5Total assets, Q2 FY2024, at 2024-06-30$91.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure61.6Total assets, Q3 FY2024, at 2024-09-30$61.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure73.4Total assets, FY2024, at 2024-12-31$73.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure73.9Total assets, Q1 FY2025, at 2025-03-31$73.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure78.5Total assets, Q2 FY2025, at 2025-06-30$78.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure82.3Total assets, Q3 FY2025, at 2025-09-30$82.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure82.3Total assets, FY2025, at 2025-12-31$82.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure102Total assets, Q1 FY2026, at 2026-03-31$102.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure110Total assets, Q2 FY2026, at 2026-06-30$110.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Current liabilities$m43.4Current liabilities, Q3 FY2023, at 2023-09-30$43.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure45.5Current liabilities, FY2023, at 2023-12-31$45.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-17, accession 0001558370-25-003039.Report this figure54.8Current liabilities, Q1 FY2024, at 2024-03-31$54.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure58.0Current liabilities, Q2 FY2024, at 2024-06-30$58.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure24.2Current liabilities, Q3 FY2024, at 2024-09-30$24.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure25.6Current liabilities, FY2024, at 2024-12-31$25.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure24.3Current liabilities, Q1 FY2025, at 2025-03-31$24.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure24.1Current liabilities, Q2 FY2025, at 2025-06-30$24.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure21.9Current liabilities, Q3 FY2025, at 2025-09-30$21.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure26.5Current liabilities, FY2025, at 2025-12-31$26.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure27.4Current liabilities, Q1 FY2026, at 2026-03-31$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure31.4Current liabilities, Q2 FY2026, at 2026-06-30$31.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Total liabilities$m49.3Total liabilities, Q3 FY2023, at 2023-09-30$49.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure50.9Total liabilities, FY2023, at 2023-12-31$50.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-17, accession 0001558370-25-003039.Report this figure60.0Total liabilities, Q1 FY2024, at 2024-03-31$60.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure63.0Total liabilities, Q2 FY2024, at 2024-06-30$63.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure29.1Total liabilities, Q3 FY2024, at 2024-09-30$29.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure30.2Total liabilities, FY2024, at 2024-12-31$30.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure28.7Total liabilities, Q1 FY2025, at 2025-03-31$28.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure28.6Total liabilities, Q2 FY2025, at 2025-06-30$28.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure29.4Total liabilities, Q3 FY2025, at 2025-09-30$29.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure34.1Total liabilities, FY2025, at 2025-12-31$34.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure35.1Total liabilities, Q1 FY2026, at 2026-03-31$35.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure38.9Total liabilities, Q2 FY2026, at 2026-06-30$38.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m38.2Shareholders' equity, Q3 FY2023, at 2023-09-30$38.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure33.6Shareholders' equity, FY2023, at 2023-12-31$33.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-18, accession 0001104659-26-029858.Report this figure29.8Shareholders' equity, Q1 FY2024, at 2024-03-31$29.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure28.6Shareholders' equity, Q2 FY2024, at 2024-06-30$28.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure32.4Shareholders' equity, Q3 FY2024, at 2024-09-30$32.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure43.2Shareholders' equity, FY2024, at 2024-12-31$43.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure45.2Shareholders' equity, Q1 FY2025, at 2025-03-31$45.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure49.9Shareholders' equity, Q2 FY2025, at 2025-06-30$49.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure52.9Shareholders' equity, Q3 FY2025, at 2025-09-30$52.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure48.2Shareholders' equity, FY2025, at 2025-12-31$48.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure67.2Shareholders' equity, Q1 FY2026, at 2026-03-31$67.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure71.4Shareholders' equity, Q2 FY2026, at 2026-06-30$71.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure

Cash flow

Operating cash flow−$10.4m, Q2 FY2026
Capital expenditure$593.0k, Q2 FY2026
Protalix BioTherapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(6.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001558370-24-015612. Derived: 9-month figure less the 6-month figure.Report this figure3.6Operating cash flow, Q4 FY2023, three months to 2023-12-31$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure4.2Operating cash flow, Q1 FY2024, three months to 2024-03-31$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure(3.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001558370-25-011471. Derived: 6-month figure less the 3-month figure.Report this figure4.1Operating cash flow, Q3 FY2024, three months to 2024-09-30$4.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110824. Derived: 9-month figure less the 6-month figure.Report this figure4.0Operating cash flow, Q4 FY2024, three months to 2024-12-31$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure(5.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure(5.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094444. Derived: 6-month figure less the 3-month figure.Report this figure(3.7)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110824. Derived: 9-month figure less the 6-month figure.Report this figure2.0Operating cash flow, Q4 FY2025, three months to 2025-12-31$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure22.0Operating cash flow, Q1 FY2026, three months to 2026-03-31$22.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure(10.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094444. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.4Capital expenditure, Q3 FY2023, three months to 2023-09-30$447.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001558370-24-015612. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$250.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure0.6Capital expenditure, Q1 FY2024, three months to 2024-03-31$598.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure0.2Capital expenditure, Q2 FY2024, three months to 2024-06-30$172.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001558370-25-011471. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$87.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001104659-25-110824. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2024, three months to 2024-12-31$425.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$306.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.4Capital expenditure, Q2 FY2025, three months to 2025-06-30$431.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001104659-26-094444. Derived: 6-month figure less the 3-month figure.Report this figure0.5Capital expenditure, Q3 FY2025, three months to 2025-09-30$498.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001104659-25-110824. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2025, three months to 2025-12-31$403.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001104659-26-029858. Derived: 12-month figure less the 9-month figure.Report this figure0.8Capital expenditure, Q1 FY2026, three months to 2026-03-31$761.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure0.6Capital expenditure, Q2 FY2026, three months to 2026-06-30$593.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001104659-26-094444. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)82.56m, Q2 FY2026
Protalix BioTherapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares49.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3049,498,105 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-06, accession 0001558370-23-017664.Report this figure57.5Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3157,480,009 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001558370-24-007695.Report this figure83.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3083,200,641 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001558370-24-012134.Report this figure83.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3083,782,679 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001558370-24-015612.Report this figure73.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3173,036,569 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0001558370-25-007063.Report this figure73.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3073,308,281 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001558370-25-011471.Report this figure81.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3081,217,068 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure76.6Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3176,611,980 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure81.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3081,271,610 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure80.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3080,814,564 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110824.Report this figure83.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3183,048,596 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-059756.Report this figure82.6Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3082,560,235 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure

Shares outstanding: 80.57mShares outstanding, period not labelled, at 2026-08-0180,571,642 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094444.Report this figure at Aug 1, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.